INV-202 is under clinical development by Inversago Pharma and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase I drugs for Type 1 Diabetes (Juvenile Diabetes) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INV-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INV-202 is under development for the treatment of type I diabetes, pre-diabetes/impaired glucose tolerance, abdominal obesity, hypertriglyceridemia, diabetic nephropathy, type 2 diabetes, non-alcoholic steatohepatitis (NASH). The drug candidates are administered through oral route. They act by targeting cannabinoid receptor 1 (CB1R).
Inversago Pharma overview
Inversago Pharma is a preclinical-stage biotech company. The company develops peripherally-restricted cannabinoid receptor 1, a G protein-coupled cannabinoid receptor that is encoded by the CNR1 gene for the treatment of Prader-Willi Syndrome, Type-1 Diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis.
For a complete picture of INV-202’s drug-specific PTSR and LoA scores, buy the report here.